|
|
|
| |
|
|
|
|
Custom LNA*
(Lock Nucleic Acid Synthesis) Locked
Nucleic Acid (LNA) was first described by Wengel and
co-workers in 19981 as a novel class of
conformationally restricted oligonucleotide analogues.
LNA is a bicyclic nucleic acid where a ribonucleoside
is linked between the 2'-oxygen and the 4'-carbon
atoms via a methylene unit.
Oligonucleotides containing LNA exhibit unprecedented
thermal stability towards complementary DNA and RNA2,
which allows excellent mismatch discrimination. In
fact the high binding affinity of LNA oligos is recommended
for use in any hybridization assay that requires high
specificity and/or reproducibility such as |
|
|
|
|
|
 |
Dual labeled
probes |
|
In situ hybridization
probe |
|
|
|
|
|
Allele Specific
PNA |
|
mRNA sample preparation |
|
|
|
 |
|
|
| As a result
of these significant characteristics, the use of LNA-modified
oligos in antisense drug development is now coming under
investigation4, and recently the therapeutic
potential of LNA has been reviewed.5 |
|
|
|
| BSI offers LNA synthesis
great flexibility. For more information on custom LNA
synthesis, call 800-227-0627 or write to
us at biosyn@biosyn.com |
|
|
| |
| |
| Features: |
|
Deprotected, desalted
and ready to use |
|
Multi-scale capacities |
|
Purification by PAGE
or RP-HPLC upon request |
|
QC analysis by MALDI-TOF
Mass spectrometry, HPLC, PAGE analysis |
|
Fast delivery with
high throughput capacity |
|
| |
|
References:
(1a) A.A. Koshkin, S.K. Singh, P. Nielsen, V.K.
Rajwanshi, R. Kumar, M. Meldgaard, C.E. Olsen,
and J. Wengel, Tetrahedron,1998, 54, 3607-3630.
(1b) S.K. Singh, P. Nielsen, A.A. Koshkin, and
J. Wengel, Chem. Comm., 1998, (4), 455-456.
(2) L. Kværnø and J. Wengel, Chem. Comm., 1999,
(7), 657-658.
(3) P. Mouritzen, A.T. Nielsen, H.M. Pfundheller,
Y. Choleva, L. Kongsbak, and S. Møller, Expert
Review of Molecular Diagnostics, 2003, 3(1),
27-38.
(4a) J. Kurreck, E. Wyszko, C. Gillen, and V.A.
Erdmann, Nucleic Acids Res., 2002, 30, 1911-1918.
(4b)H. Ørum and J. Wengel, Curr. Opinion in
Mol. Therap., 2001, 3, 239-243.
(5a) M. Petersen and J. Wengel, Trends in Biotechnology,
2003, 21(2), 74-81.
(5b) D.A. Braasch, D.R. Corey, Biochemistry,
2002, 41, 4503-4510. |
| |
|
|
|
*License Agreement: Locked-nucleic Acid (LNA) phosphoramidites are protected by EP Pat No. 1013661, US Pat No. 6,268,490 and foreign applications and patents owned by Exiqon A/S. Products are made and sold under a license from Exiqon A/S. Products are for research purposes only. Products may not be used for diagnostic, clinical, commercial or other use, including use in humans. There is no implied license for commercial use, including contract research, with respect to the products and a license must be obtained directly from Exiqon A/S for such use." |
| |
| The most trusted name in Quality
Custom Synthesis. |
|
|
|
|
|
|
